Briggs Morrison - Sep 14, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Sep 14, 2022
Transactions value $
-$4,396,277
Form type
4
Date filed
9/16/2022, 05:34 PM
Previous filing
Jul 5, 2022
Next filing
Sep 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $631K +87.6K +491.39% $7.20 105K Sep 14, 2022 Direct
transaction SNDX Common Stock Sale -$2.09M -87.6K -83.09% $23.80 17.8K Sep 14, 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $481K +66.8K +374.38% $7.20 84.6K Sep 15, 2022 Direct
transaction SNDX Common Stock Sale -$1.62M -66.8K -78.92% $24.20 17.8K Sep 15, 2022 Direct F1, F3
transaction SNDX Common Stock Options Exercise $518K +72K +403.49% $7.20 89.8K Sep 16, 2022 Direct
transaction SNDX Common Stock Sale -$1.67M -72K -80.14% $23.22 17.8K Sep 16, 2022 Direct F1, F4
transaction SNDX Common Stock Options Exercise $578K +53K +297.34% $10.90 70.9K Sep 16, 2022 Direct
transaction SNDX Common Stock Sale -$1.23M -53K -74.83% $23.22 17.8K Sep 16, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -87.6K -100% $0.00* 0 Sep 14, 2022 Common Stock 87.6K $7.20 Direct F5
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -66.8K -100% $0.00* 0 Sep 15, 2022 Common Stock 66.8K $7.20 Direct F5
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -53K -100% $0.00* 0 Sep 16, 2022 Common Stock 53K $10.90 Direct F5
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -72K -100% $0.00* 0 Sep 16, 2022 Common Stock 72K $7.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 948,946 options to purchase shares of common stock that are vested and immediately exercisable and a total of 245,042 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $23.36 to $24.01
F3 The sale prices ranged from $23.36 to $24.64
F4 The sale prices ranged from $22.96 to $23.99
F5 This option is fully vested.